IFM Investors Pty Ltd Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

IFM Investors Pty Ltd bought a new position in United Therapeutics Co. (NASDAQ:UTHR) during the 1st quarter, Holdings Channel reports. The fund bought 9,742 shares of the biotechnology company’s stock, valued at approximately $2,238,000.

A number of other hedge funds also recently bought and sold shares of the business. First Trust Direct Indexing L.P. lifted its holdings in United Therapeutics by 38.0% in the 1st quarter. First Trust Direct Indexing L.P. now owns 2,107 shares of the biotechnology company’s stock worth $484,000 after buying an additional 580 shares during the period. State of Alaska Department of Revenue increased its stake in shares of United Therapeutics by 153.5% during the first quarter. State of Alaska Department of Revenue now owns 16,557 shares of the biotechnology company’s stock valued at $3,802,000 after buying an additional 10,025 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of United Therapeutics by 0.3% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 101,042 shares of the biotechnology company’s stock valued at $23,211,000 after acquiring an additional 338 shares in the last quarter. MBM Wealth Consultants LLC boosted its holdings in United Therapeutics by 2.7% in the first quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock valued at $515,000 after acquiring an additional 59 shares in the last quarter. Finally, State of Michigan Retirement System boosted its holdings in United Therapeutics by 2.5% in the first quarter. State of Michigan Retirement System now owns 12,232 shares of the biotechnology company’s stock valued at $2,810,000 after acquiring an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total value of $3,548,850.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at $30,756.70. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $7,880,130.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $30,756.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 136,990 shares of company stock worth $32,239,641. 12.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on UTHR shares. Wedbush reaffirmed an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. The Goldman Sachs Group raised United Therapeutics from a “sell” rating to a “neutral” rating and increased their target price for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. HC Wainwright restated a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, SVB Leerink started coverage on United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 price target on the stock. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $294.25.

United Therapeutics Stock Down 0.9 %

UTHR stock traded down $2.10 on Friday, reaching $233.85. 369,691 shares of the company traded hands, compared to its average volume of 473,041. The firm has a fifty day simple moving average of $233.74 and a 200-day simple moving average of $228.81. The company has a market cap of $11.00 billion, a P/E ratio of 11.79 and a beta of 0.52. United Therapeutics Co. has a one year low of $204.44 and a one year high of $261.54. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The firm had revenue of $614.70 million for the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company’s quarterly revenue was up 25.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.67 earnings per share. Research analysts anticipate that United Therapeutics Co. will post 23.45 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.